Please wait
NEIMETH (NEIMETH) is listed on the Nigerian Exchange in the HEALTHCARE sector, with exposure to Pharmaceutical Preparations. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
HEALTHCARE
₦35.3B
N/A
36.03
Current price
₦8.25
Updated Updated 3 min ago
Conviction
68/100
Confidence
Low
Market tone
neutral · 50/100
Entry
Medium · 68/100
Recent price action for NEIMETH, so the page starts with the stock itself before the deeper analysis.
At least one liquidity signal is strong now, though large orders should still be staged.
Valuation view
Priced richer than peers
Income view
Income signal not strong yet
Market tone
neutral (50/100) — price action, attention, and recent context all lean here.
Entry view
Medium (68/100) — The company is profitable on the latest reported numbers.
Neimeth is a Nigerian pharmaceutical company that makes and sells medicines and other health products. It earns money by selling those products to hospitals, pharmacies, wholesalers and through distribution partners.
Investors usually follow NEIMETH for its valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Insider buy: VALENTINE CHINEDU OKELU
Position: Managing Director/CEO b. Bought on 3 Jun 2026, at ₦10.45 per share. From an official NGX DirectorsDealings filing. Supporting filing text captured.
Director dealings
21
Reported buys, sells, and mixed dealings.
Corporate actions
3
Dividend and company notices.
Market events
0
Insider, filing, dividend, and price events.
Source records
14
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 68/100 while today's volume is only 16% of average. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Sentiment
Market mood from flow, events, and attention.
ROE
43.7%
Return on equity
ROA
10.9%
Return on assets
Debt / equity
3.47
Lower is usually safer.
P/B ratio
0.64
Useful for book value support.
77/100
Direction
Cautious
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Volatility is elevated, so the path can stay rough even if the thesis is right.
Fair value
₦4.35
Analyst view
n/a
Forecast refresh
Updated 15h ago
Quality score
74
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
Updated 3 min ago
Bulk intraday company price snapshot from NGXPulse.
NGX Pulse bulk price snapshot
Updated 6h ago
Bulk intraday company price snapshot from NGXPulse.
NGX Pulse bulk price snapshot
Updated 1d ago
Bulk intraday company price snapshot from NGXPulse.
NGX Pulse bulk price snapshot
Updated 2d ago
Bulk intraday company price snapshot from NGXPulse.
Price points saved
50
Latest market date
2026-06-25
additional ₦30bn capital raise (total mandate ₦50bn)
NEIMETH may benefit from additional ₦30bn capital raise (total mandate ₦50bn). Confidence 90%.
Shareholders unanimously approved an additional ₦30 billion capital raise, increasing the total fundraising mandate to ₦50 billion.
capital raise
NEIMETH may benefit from capital raise. Confidence 90%.
Shareholders approved an additional N30 billion capital raise, increasing the company's fundraising mandate to N50 billion.
capital raising
NEIMETH may benefit from capital raising. Confidence 90%.
Shareholders approved raising up to N150 billion in fresh capital to strengthen the bank's capital base and support growth.
capital_raise
NEIMETH may benefit from capital_raise. Confidence 90%.
Shareholders approved raising up to N150 billion to support growth and strengthen the bank's capital base.
capital_raising
NEIMETH may benefit from capital_raising. Confidence 90%.
Shareholders approved raising up to N150 billion to strengthen the bank's capital base and support growth.
Sector spillover signals
No sector spillover signal has been linked yet.
NEIMETH
NEIMETH
Price: ₦8.25
P/E: 36.03
Yield: N/A
EKOCORP
EKOCORP
Price: ₦5.80
P/E: N/A
Yield: N/A
FIDSON
FIDSON
Price: ₦101.20
P/E: 21.95
Yield: 1.5%
MAYBAKER
MAYBAKER
Price: ₦40.00
P/E: 15.11
Yield: 1.0%
Industry
Pharmaceutical Preparations
Founded
1957
Employees
212
Ticker
NEIMETH
0.64
